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Cytomegalovirus (CMV) infection is one of the leading infectious complications postallogelneic hematopoietic stem cell transplantation 
(HSCT). Infection is observed in 60% to 70% of cases 
in the first 3 months and CMV pneumonia may develop 
in about a third of cases if no preventive measures are 
taken.1 CMV seropositivity in Eastern Mediterranean2 
and certain Asian countries is reported to be close to 
100%; hence, the need for an effective prelemptive 
treatment strategy that has low toxicity.
Prelemptive treatment with intravenous ganciclol
vir (GCV) or foscarnet often requires hospitalization 
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BACKGROUND: cytomegalovirus (cmV) infection is a major infectious complication post-allogeneic hemato-
poietic stem cell transplantation (hsct). cmV seropositivity in eastern mediterranean and certain asian coun-
tries is reported to be close to 100%; hence, the need for effective pre-emptive treatment strategy that has low 
toxicity. Valganciclovir (VGc) is a prodrug of ganciclovir with high bioavailability.
PATIENTS AND METHODS: hsct patients with documented cmV infection (as defined by positive cmV anti-
genemia) were treated as outpatients with VGc at a starting dose of 900 mg twice daily for 1 week. those who 
were antigenemia negative after one week received 900 mg once daily for another week and treatment was 
subsequently discontinued. those who were positive after one week of therapy continued on the twice daily 
treatment schedule for another week and changed to a daily schedule once they converted to antigenemia 
negativity. 
RESULTS: from January 2004 to december 2007, 47 hsct patients received preemptive treatment with VGc 
for 61 episodes of cmV infection. the antigenemia range was 1 to 700 infected cells/slide. complete responses 
were observed in 92% and 97% after the 1st and 2nd week of treatment, respectively. three percent of the epi-
sodes were considered refractory, requiring alternative therapy. no cmV disease was observed in this cohort. 
CONCLUSION: neutropenia was the main observed toxicity, requiring granulocyte-colony stimulating factor 
in 8 episodes. outpatient treatment of cmV infection with “short-course oral VGc” given as a one week twice 
daily treatment and one week once daily maintenance is a highly effective therapy with minimal toxicity. these 
results require validation in a larger, randomized study.
and parenteral access with its potential complications. 
Furthermore, treatment is inconvenient to patients and 
has a high administration cost. Extended treatment 
with ganciclovir has been shown to be associated with 
increased toxicity,3 late CMV infection and it may inl
terfere with the antilCMV Tlcell specific immunity.4 
Oral valganciclovir (VGC) is a monovalyl ester of GCV 
with highly improved bioavailability. The safety and efl
ficacy of VGC have been demonstrated in HIV5 and 
solid organ transplantation patients.6,7 Furthermore, 
prospective, randomized studies have shown that oral 
VGC leads to higher exposure to GCV than intravel
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nous GCV in allogeneic SCT patients. Einsele et al 
demonstrated that VGC at an oral dose of 900 mg 
twice daily resulted in significantly higher exposure to 
GCV (AUC0l12) than 10 mg/kg/day of intravenous 
GCV, even in patients with grade I to II intestinal graftl
vslhost disease. Furthermore, they showed that the abl
solute bioavailability of GCV is close to 75%, both in 
patients with or without grade IlII intestinal GVHD.8 
Given these early encouraging reports, we designed a 
pilot study of a simplified short course of oral VGC as 
preemptive therapy for CMV infection and examined 
its safety and efficacy in allogeneic HSCT patients.
PATIENTS AND METHODS
From January 2004 to December 2007, 47 adult pal
tients (age >14 years) who underwent allogeneic stem 
cell transplantation at King Faisal Specialist Hospital 
and Research Centre received prelemptive treatment 
for CMV infection with VGC. Patients had to have 
neutrophil recovery post HSCT (absolute neutrol
phil count greater than 0.75×109/L on two consecul
tive readings). Patients who were unable to take oral 
medications, those with active gastrointestinal GVHD, 
creatinine clearance of <25 mL/min or who had establ
lished CMV disease were excluded from this study. The 
protocol was approved by the research ethics committee 
of our institution.
All donors and 44 of the 47 recipients were seroposl
itive for CMV. Stem cell source was bone marrow in 30 
(63.8%), peripheral blood in 13 (27.6%) and cord blood 
in 4(8.5%) cases. Conditioning regimen was myeloablal
tive in 38 (80.9%) and reduced intensity in 9 (19.1%). 
GVHD prophylaxis consisted of short course of methl
otrexate (on day 1, 3 and 6) and cyclosporine (CSA). 
Underlying disease was neoplastic in 41 (87.2%) and 
nonlneoplastic in 6 (12.8%) patients. Patient characterl
istics are shown in Table 1.
CMV status was monitored by weekly testing of 
pp65 antigenemia in peripheral blood until day 120 
and for a longer period in patients receiving immunol
suppressive therapy. Treatment was given to those pal
tients who had episodes of CMV infection as defined 
by positive pp65 CMV antigenemia at any level. VGC 
was commenced at 900 mg orally twice daily for 1 week. 
Those who were CMV antigenemia negative after one 
week of twice daily treatment received 900 mg once 
daily for another week; treatment was subsequently 
discontinued on obtaining a second negative antigenl
emia result. Those who were positive continued on a 
twice daily schedule for another week and changed to a 
once daily schedule once they converted to antigenemia 
negativity. Two consecutive negative results were conl
Table 1. Patient characteristics.
Characteristics  No. %
Age (years)
  Median 27
  Range 15-51
Sex
  Male                                     27 57.4
  Female 20 42.6
Disease
  Acute myeloblastic leukemia                                         19 40.4
  Acute lymphoblastic leukemia                                       14 29.8
  Chronic myeloid leukemia                                             3 6.4
  Biphenotypic acute leukemia                                        5 10.6
  Severe aplastic anemia 6 12.8
Conditioning
  Busulphan/cyclophosphamide 20 42.6
  Cyclophosphamide/total body irradiation 18 38.3
  Fludarabine/cyclophosphamide 6 12.8
  Fludarabine/busulphan     2 4.3
  Busulphan/cyclophosphamide/ATG 1 2.1
Stem cell source  
  Bone marrow      30 63.8
  Peripheral blood 13 27.7
  Umbilical cord blood 4 8.5
GVHD prophylaxis
  Methotrexate/cyclosporine 47 100
Table 2. Treatment results.
 No % 
Number of episodes 61 100
NA1 56 92
NA2 3 5
Refractory 2 3
Requirement of G-CSF 8 13
NA1= negative antigenemia after one week of therapy
NA2= negative antigenemia after two  weeks of therapy
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sidered indicative of successful therapy. For each CMV 
infective episode, achievement of antigenemia negativl
ity was considered as indicative of a complete response. 
Patients with persistent CMV antigenemia positivity 
after two weeks of twice daily treatment were considl
ered refractory and were offered alternative treatment 
(Figure 1). 
All patients were monitored weekly with white 
blood cell count and differential, hemoglobin, platelet 
count along with liver function tests (bilirubin, transl
aminases, and alkaline phosphatase), renal function 
test (serum creatinine, electrolytes). Patients who had 
low blood counts, impaired liver or renal function were 
monitored more frequently. Those who developed sigl
nificant neutropenia (absolute neutrophil count less 
than 1×109/L) received granulocytelcolony stimulating 
factor (GlCSF) support to maintain neutrophil count 
>1×109/L. 
As per our institutional guidelines, all patients rel
ceived prophylactic acyclovir, fluconazole and triml
ethoprim/sulfamethoxazole while on immunosuppresl
sive therapy. Acyclovir was discontinued while patients 
were on VGC. All blood products were irradiated and 
leucodepleted. 
RESULTS
Fortylseven patients developed 61 episodes of CMV 
infection (as defined by positive antigenemia) and rel
ceived prelemptive treatment with VGC. The range of 
antigenemia positivity was between 1 to 700 infected 
cells/slide with a median of six infected cells/slide. 
After the first week of therapy, complete response was 
observed in 92% of the episodes, while 5% of the epil
sodes required 2 weeks of treatment to achieve complete 
response. Two episodes (3%) were refractory due to 
failure to achieve negative antigenemia after two weeks 
of therapy and required alternative therapy (Table 2). 
Twentylnine (62%) patients had acute GVHD requirl
ing steroid therapy; additional GVHD treatment(s) 
were required in steroid refractory cases. No CMV disl
ease was observed in this cohort.
Ten patients developed 14 episodes of relapsed 
CMV infection (as defined by recurrence of CMV 
antigenemia positivity), occurring 1 to 3 months after 
achieving initial remission. All were treated on the same 
protocol with VGC, achieving complete remission again 
in 12 of these episodes. 
VGC was well tolerated. All patients were complil
ant with VGC as noted during clinic monitoring. The 
most remarkable toxicity was neutropenia that required 
GlCSF support in 8 episodes, with a range of 1 to 5 
doses of GlCSF being administered during these epil
sodes. Two additional patients were on GlCSF support 
for their neutropenic recovery prior to the start of VGC 
treatment. A decrease in hemoglobin and platelets levl
els were also observed but no patients required transful
sion support.
Renal impairment was observed in 9 episodes as 
measured by a rise in serum creatinine level from basel
line. Mean serum creatinine levels prior to the start 
and after completion of VGC were 69 mmol/L and 76 
mmol/L, respectively. However, GFR did not drop to a 
level requiring discontinuation or modification of VGC 
dose. In 9 episodes, the baseline creatinine was more 
than 100 mmol/L. When clinically indicated, intravel
nous hydration was carried out in the outpatient inful
sion center. Serum creatinine improved to baseline levels 
after completion of therapy in all but one episode where 
it remained elevated. However, this patient was found 
to have recurrence of retroperitoneal mass due to exl
tramudullary disease relapse, causing obstruction of the 
left ureter. No liver function abnormality was observed 
in any of the episodes. No patients had interruption of 
therapy due to hematological or biochemical toxicity.
DISCUSSION
Untreated cases of CMV infection postallogeneic 
HSCT end up with CMV disease, particularly CMV 
pneumonia, which is fatal in up to 50% of cases.1,9l11 
Keeping in mind the threat of a deadly outcome, the 
strategy of preemptive therapy is now universal. Most 
Patients with CMV infection
Valganciclovir 900 mg BID for 1 week
Analyze antigenemia after 1 
week of therapy
Re-analyze 
antigenemia 
Valganciclovir 900 mg QD for 
1 week maintenance
Discontinue 
therapy
Continue valganciclovir 900 mg 
BID for another week
Valganciclovir 900 mg 
QD for 1 week 
maintenance
Refractory, consider 
alternative therapy
Re-analyze 
antigenemia 
-ve
-ve -ve
+ve
+ve
Figure 1. Study design.
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studies recommend close monitoring of CMV viremia 
up to 100 days post HSCT, although monitoring frel
quency and duration of therapy remain controversial. 
Boeckh et al showed that 80% of CMV disease cases 
are documented within 270 days of engraftment.12 This 
observation suggests that monitoring for CMV infecl
tion may be warranted up to this period. Closer and 
extended monitoring for CMV infection is needed for 
patients with a history of GVHD requiring immunol
suppressive therapy.
GCV is the current standard preemptive therapy 
for CMV infection;13,14 however, it requires repeated 
parenteral administration through good and durable 
intravenous access, and usually necessitates admission 
to inpatient care or treatment in outpatient hospital day 
units. Furthermore, use of GCV is a significant inconl
venience to HSCT patients.
VGC is an oral proldrug of GCV that has been 
shown to be as effective when administered prophylacl
tically to prevent CMV infection in HSCT.15 Its effil
cacy against CMV infection has been confirmed by in 
vivo and in vitro studies.16l20 However, as a preemptive 
therapy for CMV infection, the dose and duration of 
therapy have not been wellldefined. Using VGC for a 
continuous course of 4 weeks as preemptive CMV therl
apy, Busca et al reported a 40% rate of hematological 
toxicity, leading to discontinuation of therapy in some 
patients.21 Furthermore, some reports suggest that exl
tended therapy may interfere with antilCMV cellular 
immunity and is possibly associated with higher likelil
hood of late CMV infection.12,22l24
We designed a single institution pilot study of CMV 
antigenemialguided preemptive treatment of CMV inl
fection with “short course” oral VGC. Our results sugl
gest that oral VGC is highly effective as preemptive 
CMV therapy postlHSCT. In addition to high efficacy, 
this treatment approach is associated with significant 
manpower and cost savings, as well as being more conl
venient to patients.
The drug was well tolerated by all the patients and 
although there was a significant number of relapses 
(27%), reltreatment was effective and none developed 
CMV disease. The rate of CMV infection relapse is 
reported to be up to 40% in other smaller studies usl
ing VGC as preemptive therapy.21,25 Toxicity of VGC 
was similar to that generally reported with intravenous 
GCV and is easily manageable with supportive meal
sures.15 The most common toxicities were neutropenia 
and renal impairment, which were successfully managed 
with GlCSF administration and intravenous hydration, 
respectively. Although a drop in hemoglobin level was 
observed, this was mild and no patients required red 
cell transfusion. Similarly, thrombocytopenia was also 
mild and none of the patients had bleeding manifestal
tions or required platelet transfusion.    
In our institution, the observed occurrence of acute 
GVHD postallogeneic transplant for all patients is apl
proximately 36% (data not yet published). In this col
hort the rate of GVHD was significantly higher (62%), 
which may indirectly be related to the presence of CMV 
infection in these patients. Earlier studies showed a 
higher rate of GVHD in patients with positive prel
transplant CMV seropositivity, with the resultant negal
tive impact on transplantlrelated mortality and overall 
outcome.10,26
In conclusion, our study suggests that outpatient 
treatment of CMV infection with short course oral 
valganciclovir given as one week twice daily treatment 
and one week once daily maintenance is highly effective 
therapy with minimal toxicity. The treatment is very 
convenient for patients and has the potential to make a 
significant savings in administrative and labor costs. 
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